Kinase Inhibitors Synthesis, Medicinal Effects, and Applications

Chapter 1: Kinase Inhibitors: Synthesis and Applications
1. Introduction
2. Types of kinase inhibitors
2.1. Type I kinase inhibitors
2.2. Type II kinase inhibitors
2.3. Type III kinase inhibitors
2.4. Type IV kinase inhibitors
2.5. Type V kinase inhibitors
2.6. Type VI kinase inhibitors
3. Synthesis of kinase inhibitors
4. Applications of kinase inhibitors
4.1. Kinase inhibitors in cancer therapy
4.2. Kinase inhibitors in Inflammatory and Autoimmune Diseases
4.3. Kinase inhibitors in Cardiovascular Diseases
4.4. Kinase inhibitors in Parkinson’s disease
4.5. Kinase inhibitors in glaucoma
5. Limitations of kinase inhibitors
6. Future Directions
7. Conclusion
References

Chapter 2: Kinase Inhibitors in Cancer Therapy
1. Introduction
2. Kinase Inhibitors in Cancer Therapy
2.1. BCR-ABL protein inhibitor
2.2. Anaplastic lymphoma kinase (ALK) inhibitors
2.3. Epidermal growth factor receptor (EGFR) inhibitors
2.4. Vascular Endothelial Growth Factor (VEGF) Inhibitors
2.5. Janus kinases (JAKs) Inhibitors
2.6. MAPK Inhibitors
3. Opportunities and Challenges of Kinase Inhibitors in Cancer Therapy
4. Conclusion
References

Chapter 3: In-silico Approaches for the Design of Kinase Inhibitors as Anticancer Agents
1. Introduction
1.1. Kinases in Oncology
2. Protein Kinases and Their Therapeutic Significance
3. Discussion
3.1. Protein kinase’s Importance
3.2. Protein Kinase Structure and the Mechanism of Inhibition
3.3. Advancements in Kinase-Targeting Therapies and Proteomic Technologies
3.3.1. The 7 types of kinase inhibitors (Type I–VII)
3.4. Drug target of kinases
3.5. Anticancer agents
3.5.1. Gleevec
3.5.2. Preventing kinase activation
4. Conclusion
References

Chapter 4: Kinase inhibitors in COVID-19
1. Introduction
2. Kinase inhibitors in COVID-19
2.1. Role of Baricitinib in COVID-19
2.2. Role of Tofacitinib in COVID-19
2.3. Role of Ruxolitinib in COVID-19
2.4. Role of Nezulcitinib in COVID-19
2.5. Role of Silmitasertib in COVID-19
2.6. Role of Abemaciclib in COVID-19
2.7. Role of Fedratinib in COVID-19
2.8. Role of Dasatinib in COVID-19
2.9. Role of Erlotinib in COVID-19
2.10. Role of Gilteritinib in COVID-19
2.11. Role of Imatinib in COVID-19
2.12. Role of Nilotinib in COVID-19
2.13. Role of Osimertinib in COVID-19
2.14. Role of Saracatinib in COVID-19
2.15. Role of Sorafenib in COVID-19
2.16. Role of Sunitinib in COVID-19
3. Opportunities and Challenges of Kinase Inhibitors in COVID-19
4. Conclusion
References

Chapter 5: Kinase Inhibitors as Potential Antimicrobial Drugs
1. Introduction
2. Histidine Kinases and Two-Component Systems
3. Eukaryotic-like Serine/Threonine Kinases in Bacteria
4. Kinase Inhibitors as Antimicrobials
5. Kinase Inhibitors as Antibiotic Adjuvants
6. Conclusion
References

Biography

Dr. Biswa Mohan Sahoo - Professor at the School of Pharmacy and Life Sciences, Jatni, Bhubaneswar, Odisha. Dr. Sahoo completed his M.Pharm from L.M College of Pharmacy, Gujrat University, Ahmedabad, and PhD from the School of Pharmaceutical Education and Research, Berhampur University, Odisha. He has also completed his postgraduate diploma in Pharmaceutical Regulatory Affairs from Hamdard University, New Delhi. He has published several research and review articles in peer-reviewed journals of national and international repute. He has authored several textbooks of international repute. He has published 8 patents in India and Australia. Dr.

Mohd Amin Mir - Assistant Research Professor at Prince Mohammad Bin Fahd University Al Khobar, Kingdom of Saudi Arabia. He was Assistant Professor from 2018 to 2020, at Uttaranchal University Department of Chemistry, Dehradun, (Uttarakhand). Dr. Amin Mir had published more than 95 research articles in various International and National journals. Dr. M. Amin Mir got Young Scientist Award, Chemical Sciences, Aufau International Award 2016, Best Researcher Award in "92nd International Research Awards on Engineering, Science & Technology" Pondicherry, India organized by IOSRD, Young Researcher in Pharmaceutical Chemistry under the Allied Health Sciences Discipline, Venus International Healthcare Awards - VIHA 2018

Dr. Bimal Krishna Banik – his career, spanning significant achievements in teaching, research, mentoring, and professional service. He completed his Ph. D. degree in Chemistry from the Indian Association for the Cultivation of Science, Calcutta. Then, he pursued postdoctoral research at Case Western Reserve University, Ohio and Stevens Institute of Technology, New Jersey. Dr. Banik was a Tenured Full Professor in Chemistry and First President’s Endowed Professor in Science & Engineering at the University of Texas-Pan American. He was the Vice President of Research & Education Development at the Community Health Systems of Texas. Currently, Dr. Banik is a Full Professor at the Prince Mohammad Bin Fahd University, Kingdom of Saudi Arabia. Notably, he has been selected as a Fellow of Five International Scientific Societies and has been designated as a Distinguished Researcher/Distinguished Scientist.